KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (Diluted Average) (2020 - 2025)

CRISPR Therapeutics AG's Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $89.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 6.6% year-over-year to $89.9 million; the TTM value through Dec 2025 reached $89.9 million, up 6.6%, while the annual FY2025 figure was $89.9 million, 6.6% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $89.9 million at CRISPR Therapeutics AG, down from $91.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $91.3 million in Q3 2025 and bottomed at $75.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $79.4 million (2023), against an average of $81.8 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) rose 23.27% in 2021 before it grew 1.78% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $75.0 million in 2021, then increased by 3.65% to $77.7 million in 2022, then grew by 1.9% to $79.2 million in 2023, then rose by 6.49% to $84.4 million in 2024, then rose by 6.6% to $89.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Shares Outstanding (Diluted Average) are $89.9 million (Q4 2025), $91.3 million (Q3 2025), and $87.1 million (Q2 2025).